Tenofovir slows Parkinson disease progression
- Trial ID
- NCT06356662
- Official Title
- Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
- Goal
- Tenofovir slows Parkinson disease progression
- Phase
- PHASE1
- Status
- RECRUITING
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease
- Interventions
- Tenofovir Disoproxil Fumarate
Plain-Language Summary
Researchers are testing whether the antiviral tenofovir disoproxil fumarate can slow or modify Parkinson's by reducing brain inflammation or other processes that may contribute to dopamine neuron damage. In this Phase 1 trial tenofovir, a nucleotide reverse transcriptase inhibitor that blocks viral replication and may lower systemic inflammation, is being repurposed as an oral treatment and will be closely monitored for safety, especially kidney and liver function. No direct interaction with levodopa is expected, but the study will watch for any medication interactions or side effects. The trial enrolls adults 18 to 65 with early-to-mid Parkinson's (Hoehn and Yahr 1 to 2.5) and normal cognition (MMSE ≥24), excluding people with chronic hepatitis B or HIV, abnormal liver or kidney tests, prior brain surgery like DBS, major psychiatric or other serious medical conditions, pregnancy, or allergy to the drug.
Locations
- Guohua Zhao, Hangzhou, Zhejiang, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Tenofovir Disoproxil Fumarate. Researchers are testing whether the antiviral tenofovir disoproxil fumarate can slow or modify Parkinson's by reducing brain inflammation or other processes that may contribute to dopamine neuron damage. In this Phase 1 trial tenofovir, a nucleotide reverse transcriptase inhibitor that blocks viral replication and may lower systemic inflammation, is being repurposed as an oral treatment and will be closely monitored for safety, especially kidney and liver function. No direct interaction with levodopa is expected, but the study will watch for any medication interactions or side effects. The trial enrolls adults 18 to 65 with early-to-mid Parkinson's (Hoehn and Yahr 1 to 2.5) and normal cognition (MMSE ≥24), excluding people with chronic hepatitis B or HIV, abnormal liver or kidney tests, prior brain surgery like DBS, major psychiatric or other serious medical conditions, pregnancy, or allergy to the drug.
- Who can participate?
- Participants must be between 18 Years and 65 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 1 year and 11 months.